The Global Digital Pathology Market Size is projected to grow at a CAGR of 13.5% during the forecast period from 2026 to 2034 | DelveInsight

The Digital Pathology market is estimated at USD 1.25 billion in 2025 and is projected to reach USD 3.90 billion by 2034. Growth is anchored in regulatory clearance of whole slide imaging for primary diagnosis, the global pathologist shortage, and the integration of artificial intelligence into the pathology workflow.

DelveInsight's Digital Pathology Market Insights Report 2034 provides the current and forecast market analysis, individual leading Digital Pathology companies' market shares, challenges, Digital Pathology Market Drivers, barriers, trends, and key market Digital Pathology companies in the market.

To read more about the latest highlights related to the Digital Pathology Market @
https://www.delveinsight.com/sample-request/digital-pathology-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Digital Pathology Market Report

• In May 2026, F. Hoffmann-La Roche Ltd announced an agreement to acquire the computational pathology company PathAI for a transaction value of up to USD 1.05 billion, with completion expected in the second half of 2026, combining PathAI's platform with Roche's oncology diagnosis systems. Strategic significance: unites a leading whole slide imaging hardware franchise with a leading artificial intelligence software capability.
• In February 2026, Laboratory Corporation of America expanded its collaboration with PathAI to roll out a digital pathology platform across its anatomic pathology laboratories and hospital sites in the United States. Strategic significance: signals the transition of digital pathology from pilot deployments toward large-scale, production clinical use across a national laboratory network.
• In August 2025, Tempus AI Inc. agreed to acquire the digital pathology company Paige for USD 81 million, gaining a digitized archive of roughly 7 million whole slide images and associated clinical and molecular data spanning 45 countries. Strategic significance: underscores that strategic value in computational pathology increasingly resides in large, well-annotated image archives.
• The global Digital Pathology market is growing at a CAGR of 13.5% during the forecast period from 2026 to 2034.
• The principal drivers are rising global cancer incidence; a worsening global shortage of pathologists; regulatory clearance of whole slide imaging systems for primary diagnosis; integration of artificial intelligence and computational pathology; expansion of telepathology and remote diagnosis; growing adoption by pharmaceutical and biotechnology companies; and integration with laboratory information systems, the electronic health record, and enterprise imaging.
• The leading Digital Pathology Companies include F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Danaher Corporation, Hamamatsu Photonics K.K., 3DHISTECH Ltd., Sectra AB, FUJIFILM Holdings Corporation, Tempus AI Inc., Proscia Inc., and Indica Labs Inc., among others.

To know more about why North America is leading the market growth in the Digital Pathology Market, Get a snapshot @
https://www.delveinsight.com/sample-request/digital-pathology-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Digital Pathology Overview

Digital pathology is the discipline of converting glass microscope slides into high-resolution digital images that can be viewed, analyzed, shared, and archived electronically, transforming a workflow that has relied on the light microscope for over a century. The core technology is whole slide imaging, in which a scanner digitizes an entire stained tissue section at diagnostic resolution to create a whole slide image that a pathologist reviews on a display rather than under a microscope. The market comprises the hardware required to digitize slides, principally whole slide scanners of varying throughput; the software used to store, manage, view, annotate, and analyze images, including image management systems and increasingly artificial intelligence applications; and the storage, communication, and services layers that support enterprise deployment. The category is transitioning from early-stage digitization confined to research and education toward full-scale clinical adoption for primary diagnosis, a shift catalyzed by regulatory clearance of whole slide imaging systems for diagnostic use, an acute pathologist shortage, and the maturation of computational pathology toward multimodal foundation models.

Digital Pathology Market Key Growth Drivers

• Rising global cancer incidence, with the International Agency for Research on Cancer projecting a rise from 20 million new cases in 2022 to 35 million by 2050, increasing biopsy and histopathology volumes.
• A worsening global shortage of pathologists, which compels laboratories to adopt digital tools that improve productivity without compromising diagnostic accuracy.
• Regulatory clearance of whole slide imaging systems for primary diagnosis, which has removed the principal barrier to routine clinical adoption; by early 2025, seven whole slide imaging systems with unique scanners had received FDA clearance for primary diagnostic use, up from six in late 2024.
• Integration of artificial intelligence and computational pathology for detection, biomarker scoring, companion diagnostics, and prognosis, with a shift toward breakthrough and de novo designations exemplified by ArteraAI and Modella AI.
• Expansion of telepathology and remote diagnosis, improving access to subspecialty expertise in underserved and rural settings.
• Growing adoption by pharmaceutical and biotechnology companies for drug development, clinical trials, and companion diagnostic standardization.
• Integration of digital pathology with laboratory information systems, the electronic health record, and enterprise imaging, supported by cloud infrastructure.

Get a sneak peek at the Digital Pathology Market Dynamics @
https://www.delveinsight.com/sample-request/digital-pathology-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Digital Pathology Market Segment Analysis

The Digital Pathology market is segmented by Product (Hardware/Scanners, Software, and Storage & Communication Systems), Technology (Whole Slide Imaging, Virtual Microscopy, and Artificial Intelligence & Image Analysis), Application (Disease Diagnosis, Drug Discovery and Development, and Research and Education), End User (Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, and Academic and Research Institutes), and Geography (North America, Europe, Asia-Pacific, and Rest of World).

• By product, the hardware (scanners) segment dominated the market with a 47% share in 2025, as scanner hardware is the required infrastructure for every digital pathology program, while software is the fastest-growing category on the strength of recurring, higher-margin analytical and workflow revenue.
• By technology, whole slide imaging led with a 55% share in 2025 as the foundational substrate on which artificial intelligence and virtual microscopy both operate.
• By application, disease diagnosis accounted for 56% of the market in 2025, reflecting pathology's core clinical role, while drug discovery and development is the fastest-growing application.
• By end user, hospitals and diagnostic laboratories held a 46% share in 2025, given their role as the principal purchasers of high-throughput clinical scanners and enterprise image management systems.

Which key players in the Digital Pathology Market are set to emerge as the trendsetter, explore @
https://www.delveinsight.com/sample-request/digital-pathology-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Digital Pathology Market Competitive Landscape

The Digital Pathology market is classified as Moderately Concentrated. A small number of diagnostics and imaging companies dominate the whole slide scanner and enterprise workflow segment, where regulatory clearance and capital intensity create high barriers, while the computational pathology and artificial intelligence segment is more fragmented and rapidly consolidating through acquisition. F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Danaher Corporation (through Leica Biosystems), and Hamamatsu Photonics K.K. lead in scanners and workflow, while Tempus AI Inc., PathAI Inc., Proscia Inc., and Indica Labs Inc. lead in computational pathology. M&A is the defining competitive dynamic, exemplified by Roche's agreement to acquire PathAI for up to USD 1.05 billion, Tempus AI's acquisition of Paige, and Evident's acquisition of scanner vendor Pramana.

Digital Pathology Companies

• F. Hoffmann-La Roche Ltd
• Koninklijke Philips N.V.
• Danaher Corporation
• Hamamatsu Photonics K.K.
• 3DHISTECH Ltd.
• Sectra AB
• FUJIFILM Holdings Corporation
• Tempus AI Inc.
• Proscia Inc.
• Indica Labs Inc.
• PathAI Inc.
• Epredia
• Aiforia Technologies Plc
• Visiopharm A/S
• Deciphex Ltd.
• and others.

Digital Pathology Market Restraints

• Despite strong structural tailwinds, the market faces material constraints. The high cost and complexity of digitization, including scanners, IT infrastructure, and software integration, strains the budgets of community and smaller laboratories.
• Reimbursement pathways for digital pathology and its AI tools remain limited in many health systems, lengthening the return-on-investment horizon.
• Interoperability is complicated by the closed-loop regulatory model tying specific software to specific scanners and by proprietary image formats, which can lock laboratories into single-vendor stacks.
• Whole slide images are extremely large, creating ongoing storage, transmission, and cybersecurity demands.
• Finally, adoption requires retraining pathologists, redesigning workflows, and validating digital reading against microscopy, gating the pace of change across departments.

Interested in knowing the Digital Pathology Market by 2034? Click to get a snapshot of the Digital Pathology Market Trends @
https://www.delveinsight.com/sample-request/digital-pathology-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Scope of the Digital Pathology Market Report

• Coverage- Global
• Forecast Period- 2026-2034
• Digital Pathology Companies- F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Danaher Corporation, Hamamatsu Photonics K.K., 3DHISTECH Ltd., Sectra AB, FUJIFILM Holdings Corporation, Tempus AI Inc., Proscia Inc., Indica Labs Inc., and others.
• Digital Pathology Market Restraints and Regulatory Analysis
• Digital Pathology Market Assessment across Product, Technology, Application, End User, and Geography

Explore more information of the Digital Pathology Market Insights @
https://www.delveinsight.com/sample-request/digital-pathology-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Table of Contents

• Introduction
• Executive Summary of Digital Pathology Market
• Key Factors Impacting the Digital Pathology Market
• Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
• Regulatory Analysis
• Porter's Five Forces Analysis
• Digital Pathology Market Assessment
• Digital Pathology Market Competitive Landscape
• Digital Pathology Market Startup Funding and Investment Trends
• Digital Pathology Market Company and Product Profiles
• KOL Views
• Project Approach
• About DelveInsight
• Disclaimer and Contact Us

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.